001     138289
005     20240525120338.0
024 7 _ |a 10.1002/acn3.189
|2 doi
024 7 _ |a pmid:26000322
|2 pmid
024 7 _ |a pmc:PMC4435704
|2 pmc
024 7 _ |a altmetric:4051411
|2 altmetric
037 _ _ |a DZNE-2020-04611
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Haack, Tobias B
|b 0
245 _ _ |a Deficiency of ECHS1 causes mitochondrial encephalopathy with cardiac involvement.
260 _ _ |a Chichester [u.a.]
|c 2015
|b Wiley
264 _ 1 |3 online
|2 Crossref
|b Wiley
|c 2015-03-13
264 _ 1 |3 print
|2 Crossref
|b Wiley
|c 2015-05-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1716557890_5213
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Short-chain enoyl-CoA hydratase (ECHS1) is a multifunctional mitochondrial matrix enzyme that is involved in the oxidation of fatty acids and essential amino acids such as valine. Here, we describe the broad phenotypic spectrum and pathobiochemistry of individuals with autosomal-recessive ECHS1 deficiency.Using exome sequencing, we identified ten unrelated individuals carrying compound heterozygous or homozygous mutations in ECHS1. Functional investigations in patient-derived fibroblast cell lines included immunoblotting, enzyme activity measurement, and a palmitate loading assay.Patients showed a heterogeneous phenotype with disease onset in the first year of life and course ranging from neonatal death to survival into adulthood. The most prominent clinical features were encephalopathy (10/10), deafness (9/9), epilepsy (6/9), optic atrophy (6/10), and cardiomyopathy (4/10). Serum lactate was elevated and brain magnetic resonance imaging showed white matter changes or a Leigh-like pattern resembling disorders of mitochondrial energy metabolism. Analysis of patients' fibroblast cell lines (6/10) provided further evidence for the pathogenicity of the respective mutations by showing reduced ECHS1 protein levels and reduced 2-enoyl-CoA hydratase activity. While serum acylcarnitine profiles were largely normal, in vitro palmitate loading of patient fibroblasts revealed increased butyrylcarnitine, unmasking the functional defect in mitochondrial β-oxidation of short-chain fatty acids. Urinary excretion of 2-methyl-2,3-dihydroxybutyrate - a potential derivative of acryloyl-CoA in the valine catabolic pathway - was significantly increased, indicating impaired valine oxidation.In conclusion, we define the phenotypic spectrum of a new syndrome caused by ECHS1 deficiency. We speculate that both the β-oxidation defect and the block in l-valine metabolism, with accumulation of toxic methacrylyl-CoA and acryloyl-CoA, contribute to the disorder that may be amenable to metabolic treatment approaches.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 1
542 _ _ |i 2015-09-01
|2 Crossref
|u http://doi.wiley.com/10.1002/tdm_license_1.1
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Jackson, Christopher B
|b 1
700 1 _ |a Murayama, Kei
|b 2
700 1 _ |a Kremer, Laura S
|b 3
700 1 _ |a Schaller, André
|b 4
700 1 _ |a Kotzaeridou, Urania
|b 5
700 1 _ |a de Vries, Maaike C
|b 6
700 1 _ |a Schottmann, Gudrun
|b 7
700 1 _ |a Santra, Saikat
|b 8
700 1 _ |a Büchner, Boriana
|b 9
700 1 _ |a Wieland, Thomas
|b 10
700 1 _ |a Graf, Elisabeth
|b 11
700 1 _ |a Freisinger, Peter
|b 12
700 1 _ |a Eggimann, Sandra
|b 13
700 1 _ |a Ohtake, Akira
|b 14
700 1 _ |a Okazaki, Yasushi
|b 15
700 1 _ |a Kohda, Masakazu
|b 16
700 1 _ |a Kishita, Yoshihito
|b 17
700 1 _ |a Tokuzawa, Yoshimi
|b 18
700 1 _ |a Sauer, Sascha
|b 19
700 1 _ |a Memari, Yasin
|b 20
700 1 _ |a Kolb-Kokocinski, Anja
|b 21
700 1 _ |a Durbin, Richard
|b 22
700 1 _ |a Hasselmann, Oswald
|b 23
700 1 _ |a Cremer, Kirsten
|b 24
700 1 _ |a Albrecht, Beate
|b 25
700 1 _ |a Wieczorek, Dagmar
|b 26
700 1 _ |a Engels, Hartmut
|b 27
700 1 _ |a Hahn, Dagmar
|b 28
700 1 _ |a Zink, Alexander M
|b 29
700 1 _ |a Alston, Charlotte L
|b 30
700 1 _ |a Taylor, Robert W
|b 31
700 1 _ |a Rodenburg, Richard J
|b 32
700 1 _ |a Trollmann, Regina
|b 33
700 1 _ |a Sperl, Wolfgang
|b 34
700 1 _ |a Strom, Tim M
|b 35
700 1 _ |a Hoffmann, Georg F
|b 36
700 1 _ |a Mayr, Johannes A
|b 37
700 1 _ |a Meitinger, Thomas
|0 P:(DE-2719)9000207
|b 38
|u dzne
700 1 _ |a Bolognini, Ramona
|b 39
700 1 _ |a Schuelke, Markus
|b 40
700 1 _ |a Nuoffer, Jean-Marc
|b 41
700 1 _ |a Kölker, Stefan
|b 42
700 1 _ |a Prokisch, Holger
|0 P:(DE-HGF)0
|b 43
|e Corresponding author
700 1 _ |a Klopstock, Thomas
|0 P:(DE-2719)2810704
|b 44
|e Last author
|u dzne
773 1 8 |a 10.1002/acn3.189
|b : Wiley, 2015-03-13
|n 5
|p 492-509
|3 journal-article
|2 Crossref
|t Annals of Clinical and Translational Neurology
|v 2
|y 2015
|x 2328-9503
773 _ _ |a 10.1002/acn3.189
|g Vol. 2, no. 5, p. 492 - 509
|0 PERI:(DE-600)2740696-9
|n 5
|q 2:5<492 - 509
|p 492-509
|t Annals of Clinical and Translational Neurology
|v 2
|y 2015
|x 2328-9503
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/138289/files/DZNE-2020-04611.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/138289/files/DZNE-2020-04611.pdf?subformat=pdfa
856 7 _ |2 Pubmed Central
|u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435704
909 C O |o oai:pub.dzne.de:138289
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 38
|6 P:(DE-2719)9000207
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 44
|6 P:(DE-2719)2810704
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN CLIN TRANSL NEUR : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
920 1 _ |0 I:(DE-2719)5000050
|k Ext HZM
|l Ext HZM
|x 0
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000050
980 _ _ |a I:(DE-2719)1111016
980 1 _ |a FullTexts
999 C 5 |9 -- missing cx lookup --
|a 10.1159/000468650
|2 Crossref
|o 10.1159/000468650
999 C 5 |9 -- missing cx lookup --
|a 10.1093/hmg/ddu059
|2 Crossref
|o 10.1093/hmg/ddu059
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s10545-010-9236-x
|2 Crossref
|o 10.1007/s10545-010-9236-x
999 C 5 |9 -- missing cx lookup --
|a 10.1186/1750-1172-8-188
|2 Crossref
|o 10.1186/1750-1172-8-188
999 C 5 |9 -- missing cx lookup --
|a 10.1086/510725
|2 Crossref
|o 10.1086/510725
999 C 5 |9 -- missing cx lookup --
|a 10.1093/brain/awu216
|2 Crossref
|o 10.1093/brain/awu216
999 C 5 |9 -- missing cx lookup --
|a 10.1002/ana.410390311
|2 Crossref
|o 10.1002/ana.410390311
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.ymgme.2013.12.010
|2 Crossref
|o 10.1016/j.ymgme.2013.12.010
999 C 5 |9 -- missing cx lookup --
|a 10.1136/jmedgenet-2012-100846
|2 Crossref
|o 10.1136/jmedgenet-2012-100846
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s12033-008-9100-5
|2 Crossref
|o 10.1007/s12033-008-9100-5
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.bbagen.2014.01.025
|2 Crossref
|o 10.1016/j.bbagen.2014.01.025
999 C 5 |y 1977
|2 Crossref
|o Fong 1977
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.bcp.2011.07.103
|2 Crossref
|o 10.1016/j.bcp.2011.07.103
999 C 5 |9 -- missing cx lookup --
|a 10.1136/jmedgenet-2013-101932
|2 Crossref
|o 10.1136/jmedgenet-2013-101932
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S1388-1981(02)00296-2
|2 Crossref
|o 10.1016/S1388-1981(02)00296-2
999 C 5 |9 -- missing cx lookup --
|a 10.1038/nmeth.2890
|2 Crossref
|o 10.1038/nmeth.2890
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.ajhg.2012.10.019
|2 Crossref
|o 10.1016/j.ajhg.2012.10.019
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.ymgme.2012.02.007
|2 Crossref
|o 10.1016/j.ymgme.2012.02.007
999 C 5 |9 -- missing cx lookup --
|a 10.1001/jama.296.8.943
|2 Crossref
|o 10.1001/jama.296.8.943
999 C 5 |9 -- missing cx lookup --
|a 10.1023/A:1005556207210
|2 Crossref
|o 10.1023/A:1005556207210
999 C 5 |9 -- missing cx lookup --
|a 10.1016/B978-0-444-59565-2.00035-6
|2 Crossref
|o 10.1016/B978-0-444-59565-2.00035-6
999 C 5 |9 -- missing cx lookup --
|a 10.1067/mpd.2003.231
|2 Crossref
|o 10.1067/mpd.2003.231
999 C 5 |9 -- missing cx lookup --
|a 10.1542/peds.109.1.99
|2 Crossref
|o 10.1542/peds.109.1.99
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.lfs.2010.04.003
|2 Crossref
|o 10.1016/j.lfs.2010.04.003
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.ymgme.2005.07.030
|2 Crossref
|o 10.1016/j.ymgme.2005.07.030
999 C 5 |y 1982
|2 Crossref
|o Brown 1982


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21